Senestech (NASDAQ:SNES – Get Free Report) and TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.
Profitability
This table compares Senestech and TriSalus Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Senestech | -289.01% | -150.93% | -111.41% |
| TriSalus Life Sciences | -86.61% | N/A | -116.50% |
Institutional & Insider Ownership
5.2% of Senestech shares are held by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are held by institutional investors. 5.3% of Senestech shares are held by insiders. Comparatively, 27.5% of TriSalus Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Senestech | 0 | 1 | 0 | 1 | 3.00 |
| TriSalus Life Sciences | 0 | 0 | 6 | 2 | 3.25 |
Senestech presently has a consensus target price of $10.00, indicating a potential upside of 114.13%. TriSalus Life Sciences has a consensus target price of $10.75, indicating a potential upside of 136.26%. Given TriSalus Life Sciences’ stronger consensus rating and higher possible upside, analysts clearly believe TriSalus Life Sciences is more favorable than Senestech.
Valuation & Earnings
This table compares Senestech and TriSalus Life Sciences”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Senestech | $1.86 million | 13.11 | -$6.18 million | ($5.44) | -0.86 |
| TriSalus Life Sciences | $29.43 million | 5.85 | -$30.05 million | ($1.18) | -3.86 |
Senestech has higher earnings, but lower revenue than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Senestech, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Senestech has a beta of 0.2, indicating that its share price is 80% less volatile than the S&P 500. Comparatively, TriSalus Life Sciences has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500.
Summary
TriSalus Life Sciences beats Senestech on 10 of the 15 factors compared between the two stocks.
About Senestech
SenesTech, Inc. develops a technology for managing animal pest populations through fertility control. It offers ContraPest, a liquid bait that limits reproduction of male and female rats. The company was incorporated in 2004 and is headquartered in Phoenix, Arizona.
About TriSalus Life Sciences
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
Receive News & Ratings for Senestech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senestech and related companies with MarketBeat.com's FREE daily email newsletter.
